Compare General Dynamics Corporation (GD) vs Hims and Hers Health Inc (HIMS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
General Dynamics Corporation vs Hims and Hers Health Inc — how do they compare? General Dynamics Corporation trades at $368.03 (market cap $98.88B), while Hims and Hers Health Inc trades at $35.52 (market cap $8.60B). The key difference: General Dynamics Corporation is far larger — about 11.5× Hims and Hers Health Inc's market cap, and General Dynamics Corporation pays a 1.74% dividend while Hims and Hers Health Inc pays none. Which is the better fit depends on your goals.
| GD | HIMS | |
|---|---|---|
Market Cap | $98.88B | $8.60B |
Sector | Industrials | Health |
52-Week High | $376.88 | $66.18 |
52-Week Low | $297.05 | $14.52 |
Enterprise Value | $105.06B | $8.98B |
Dividend Yield | 1.74% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
General Dynamics (GD) trades at $369.5, down 0.88% on the day, with a bullish technical signal and strong fundamental performance. The company has beaten earnings estimates for three consecutive quarters, with Q1 2026 EPS of $4.10 surpassing the $3.67 expectation. Revenue growth is robust, reaching $52.55B in 2025, while net income margin improved to 8.07%. The stock is supported by a substantial $130.8 billion backlog and a consistent dividend, with the next payment of $1.59 scheduled for August 7, 2026.
The outlook for GD is positive, driven by strong defense spending tailwinds, naval contract dominance, and consistent earnings beats. Investment opportunities include exposure to growing submarine and C5ISR markets. Key risks involve execution on massive backlogs, potential defense budget volatility, and valuation metrics (P/E of 23.01) that are above some industry peers, requiring sustained growth to justify.
Hims & Hers Health trades at $35.52, up 1.05% today, with a bullish technical signal from moving averages and a consensus analyst price target of $33.57. Recent earnings show volatility with a Q1 2026 miss, but revenue grew to $2.35 billion in 2025. The company benefits from expansion in weight-loss therapies and a $400 million JPMorgan facility, though high valuations like a P/E of 57.14 and negative net income margin pose concerns.
Outlook is mixed: growth opportunities in telehealth and GLP-1 drugs support upside, but earnings inconsistency and regulatory risks from FDA reviews require caution. Analysts are 35% buy-rated, highlighting potential if execution improves, yet investors face volatility near key resistance at $38.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About General Dynamics Corporation
General Dynamics is a defense contractor and business jet manufacturer. The firm's segments include aerospace, combat systems, marine, and technologies. The company's aerospace segment creates Gulfstream business jets. Combat system produces land-based combat vehicles, such as the M1 Abrams tank. The marine subsegment creates nuclear-powered submarines, among other things. The technologies segment contains two main units, an IT business that primarily serves the government market and a mission systems business that focuses on products that provide command, control, computers, intelligence, surveillance, and reconnaissance capabilities to the military.
Read more on GD →About Hims and Hers Health Inc
Hims & Hers is a multi-specialty telehealth platform that provides personalized health and wellness products. It offers access to medical providers and treatments for hair loss, sexual health, and skincare.
Read more on HIMS →
